【Cited FineTest Antibody】 Current Research on Wound Healing Biomaterials

FineTest antibody contributes to the research on wound healing biomaterials. The western blot is designed to measure SSBP1 in wound sample.

Publication Details
Article Title: An IFI6-based hydrogel promotes the healing of radiation-induced skin injury through regulation of the HSF1 activity
Journal Title: Journal of Nanobiotechnology
DOI: 10.1186/s12951-022-01466-x
IF: 10.435
PMID: 35717249

Abstract: Radiation-induced skin injury (RISI) is a common complication of radiotherapy. Interferon-alpha inducible protein 6 (IFI6) significantly reduces the radiation sensitivity of HaCaT cells. Sodium alginate (SA) has substantial moisturizing properties. Graphene oxide (GO) is a suitable substrate with physical antibacterial properties. Therefore, we designed materials to modify IFI6 using the biogule of polydopamine (PDA) connected to GO/SA. The structure, size, morphology, and elemental compositions of IFI6-PDA@GO/SA were analyzed. Cytological studies suggested that IFI6-PDA@GO/SA is non-toxic to HaCaT cells, with antibacterial properties. It promotes migration and vascularization and inhibits apoptosis. These cells express IFI6 after irradiation. The mouse model suggested that IFI6-PDA@GO/SA promotes wound healing and reduces reactive oxygen species expression. IFI6-PDA@GO/SA accelerates RISI healing, possibly by initiating the SSBP1/HSF1 signaling pathway. In addition, IFI6-PDA@GO/SA improves the immune microenvironment. This study constitutes the first use of IFI6 as a RISI wound-healing material.

Keywords: Polydopamine, Graphene oxide, Sodium alginate, Interferon-alpha inducible protein 6, Radiation-induced skin injury

Western Blot

FineTest Product Sample Detection Target
anti- SSBP1 antibody (FNab08247) wound sample SSBP1

Validated Image

Wound Healing

Figure Source: J Nanobiotechnology. 2022 Jun 18;20(1):288. doi: 10.1186/s12951-022-01466-x.

Fig. 7. The mechanism of IFI6-PDA@GO/SA. A Immunohistochemistry of mouse RISI on day 14. Positive antibody expression (red arrow). B The relative expression of HSF1, SSBP1, and IFI6 IHC on day 14. C, D Western blot of HSF1, SSBP1, and IFI6. E Relative levels of ROS/NLRP3 on day 14. *P < 0.05.